Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Organ Cancer Clear all
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Malignant Lymphoma of Extranodal and/or Solid Organ Site, Solid Tumor
Interventions
CZ48
Drug
Lead sponsor
Cao Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 5:05 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, placebo
Biological · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
20
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors
Interventions
Lenalidomide, Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced May 22, 2026, 5:05 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced May 22, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced May 22, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Waldenström Macroglobulinemia
Interventions
rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced May 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced May 22, 2026, 5:05 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions
Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
Procedure · Drug · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer
Interventions
Amrubicin, Cyclophosphamide
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced May 22, 2026, 5:05 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy, Hematologic Malignancy, Solid Organ Transplant, Hematopoietic Cell Transplant, Cellular Therapy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 5:05 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Solid Organ Tumors
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Oakland, California • Boynton Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced May 22, 2026, 5:05 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
Interventions
Selumetinib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 5:05 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions
REGN10597, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
colloidal gold-bound tumor necrosis factor, pharmacological study
Biological · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced May 22, 2026, 5:05 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Advanced and/or Metastatic Solid Organ Cancer
Interventions
VB-111
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study, Sorafenib, Sorafenib Tosylate
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced May 22, 2026, 5:05 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Immunocompromised Host, Organ Transplantation, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 100 Years
Enrollment
19,929,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced May 22, 2026, 5:05 AM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Insomnia, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Placebo Administration, Single Agent Therapy
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced May 22, 2026, 5:05 AM EDT